HPVC2016-108: Biopharmaceutical - Infliximab

Current Contract

Contract start date: 01 Feb 2016

Contract end date: 29 Jan 2026

Option periods: Nil

Description

For the provision of Biopharmaceutical Infliximab 100mg vials

Additional information

Contract Details

The Principal Period commenced on 1st of February 2016 and ran until 30th of April 2018.

The first Contract Option period of two years was executed – effective from 1 May 2018 until 30 April 2020.

The second Contract Option of two years has been executed – effective from 1 May 2020 until 30 April 2022.

Contract has been extended - effective 1 May 2022 until 30 April 2024.

Contract has been extended - effective 1 May 2024 until 29 January 2026.

Option Periods Remaining

Nil